The other shoe dropped in a good way for backers of Actinium Pharmaceuticals Inc. as the firm popped the lid off full data from the phase III study called Sierra testing Iomab-B in patients age 55 and older with active relapsed or refractory acute myeloid leukemia (r/r AML). Antibody radiation conjugate (ARC) Iomab-B met the primary endpoint of durable complete remission of six months following initial complete remission after bone-marrow transplant with a high degree of statistical significance.
Nanchang Helioeast Technology Co. Ltd. has patented oxa-spirocyclic compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors and reported to be useful for the treatment of acute myeloid leukemia.
The alpha chain of the IL-3 receptor, CD123, is frequently overexpressed in acute myeloid leukemia (AML) and is considered an attractive target in the treatment of this disease. However, cytotoxic antibodies or T-cell engagers targeting CD123 have shown insufficient clinical efficacy or safety, confirming the need for alternative targeted approaches.
Poseidon Innovation LLC and the University of California have patented bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, viral infections and acute renal disorders, among others.
University of Maryland has presented proteolysis targeting chimeras (PROTACs) comprised of E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to induced myeloid leukemia cell differentiation protein Mcl-1-binding moiety through a linker reported to be useful for the treatment of cancer.
Peptide-drug conjugates are an emerging class of molecules that allow efficient targeted drug delivery into tumors. Researchers from Oncopeptides AB and their collaborators presented data on the novel peptide-drug conjugate OPDC3, which has a novel alkylating payload, in models of diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML).
Oncoprotein Myc is known to be dysregulated in about 70% of cancers, and it is highly expressed in leukemias and lymphomas. Targeting Myc has not been successful and is still an unmet clinical need for cancer patients.
Janssen Pharmaceutica NV and Johnson & Johnson (China) Investment Ltd. have identified substituted phenyl-1H-pyrrolo [2, 3-c] pyridine derivatives acting as menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
